Saturday 17 October 2026
Export CRMD’s income statement to Excel — free account
CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
7.26
0.20
−2.68%
Follow CRMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
3.26 | 2.87 | 5.26 | 5.17 |
+8 more quarters Free account |
P/S ratio |
1.33 | 1.35 | 2.69 | 4.12 | |
P/FCF ratio |
2.46 | 2.77 | 4.85 | 11.87 | |
P/Operating CF |
7.14 | 12.74 | 8.87 | 28.62 | |
P/B ratio |
1.34 | 1.24 | 2.07 | 2.36 | |
Price to Tangible BV |
8.51 | 14.10 | 0.00 | 0.00 | |
EV/Sales |
1.09 | 1.27 | 2.68 | 4.54 | |
EV/EBITDA |
1.99 | 2.31 | 5.04 | 8.97 | |
EV/Operating CF |
1.99 | 2.56 | 4.76 | 12.97 | |
EV/FCF |
2.01 | 2.60 | 4.83 | 13.07 | |
Quick Ratio |
2.23 | 2.59 | 1.83 | 1.60 | |
Current Ratio |
2.56 | 2.98 | 2.11 | 1.94 | |
Net Debt/EBITDA |
(2.09) | (0.45) | (0.06) | 1.62 | |
Debt/Assets |
16.06% | 17.76% | 17.51% | 19.32% | |
Debt/Equity |
0.32 | 0.33 | 0.36 | 0.39 | |
Asset Turnover |
0.80 | 0.83 | 0.66 | 0.52 | |
Operating CF/Net income |
3.32 | 1.10 | 6.74 | 0.28 | |
Capex/Depreciation |
(0.05) | (0.07) | (0.16) | (0.13) | |
Interest Coverage |
— | — | 32.24 | 54.15 | |
Research and Development Expense of Revenue |
6.56% | 5.66% | 6.69% | 4.89% | |
Selling, General and Administrative Expense of Revenue |
27.01% | 26.88% | 30.78% | 35.13% | |
Intangible Assets out of Total Assets |
0.43 | 0.49 | 0.50 | 0.54 | |
Share Based Compensation of Revenue |
4.01% | 3.60% | 2.79% | 3.90% | |
Graham Net Nets |
0.06 | 0.01 | (0.06) | (0.13) | |
Graham Number |
17.85 | 17.12 | 16.73 | 15.79 | |
Earnings Yield |
30.70% | 34.90% | 19.00% | 19.35% | |
Free Cash Flow Yield |
40.67% | 36.07% | 20.62% | 8.43% | |
Revenue per Share |
1.30 | 1.60 | 1.79 | 1.37 | |
Operating CF per Share |
1.10 | 0.53 | 1.31 | 0.41 | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
1.09 | 0.52 | 1.29 | 0.40 | |
Cash per Share |
3.27 | 2.24 | 2.06 | 0.73 | |
Shareholders Equity per Share |
5.87 | 5.50 | 5.63 | 4.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.87 | 5.50 | 5.63 | 4.93 | |
Free Cash Flow |
85.68 | 41.65 | 92.74 | 30.35 | |
Working Capital |
293.16 | 254.34 | 192.78 | 125.89 | |
Capital Expenditures |
(0.56) | (0.73) | (1.72) | (0.51) | |
Net Current Asset Value |
37.34 | 4.53 | (53.78) | (117.20) | |
EV/EBIT |
2.32 | 2.62 | 5.55 | 9.35 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
2.84 | 2.79 | 5.58 | 8.50 | |
| Other line items | |||||
Average Receivables |
102.11 | 104.71 | 111.44 | 87.98 | |
Average Payables |
8.03 | 7.38 | 4.80 | 10.90 | |
Average Inventory |
24.11 | 19.11 | 18.66 | 17.78 | |
Average Assets |
578.33 | 482.61 | 472.49 | 414.22 | |
Average Common Equity |
340.73 | 275.97 | 244.98 | 216.42 |
Columns are period end dates